Healthcare stocks were lower Tuesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) falling 0.1% each.

The iShares Biotechnology ETF (IBB) was shedding 1.2%.

In corporate news, Mirum Pharmaceuticals (MIRM) shares rose 2% after it said Tuesday its phase 3 trial evaluating brelovitug in chronic hepatitis delta virus met its primary endpoint.

AstraZeneca (AZN) has acquired Omniose, the preclinical biotechnology company said Tuesday. Omniose has become a subsidiary of AstraZeneca and part of the Infectious Disease Unit, the company said. AstraZeneca shares were falling 1.6%.

ADC Therapeutics' (ADCT) recent restructuring improved the company's financial position and its Lotis-7 data looked encouraging, but outlook for revenue growth remains unclear given the competitive landscape in diffuse large B-cell lymphoma, RBC Capital Markets said in a note. ADC Therapeutics shares were falling 6.5%.